CEO and President of Aeterna Zentaris stated.

Aeterna Zentari expects to document AEZS-130 NDA with FDA for adult growth hormone deficiency Aeterna Zentaris Inc. Juergen Engel, PhD, CEO and President of Aeterna Zentaris stated, ‘Although the FDA’s decision won’t allow us to submit our New Drug Program on a rolling basis, it will not impact the timing of our filing of the NDA for AEZS-130, which is certainly expected early next year, nor if the potential be suffering from it of obtaining concern review.The results of the trial were reported in the American Journal of Psychiatry. Computers rather than capsules Children are comfortable with computers, explains Prof. Bar-Haim. And because of the potential unwanted effects of medicines or the difficulty in obtaining cognitive behavioral therapy, such as the need for highly trained professionals, it is good to have an alternative procedure. ABM treatments could be disseminated on the internet or administered by employees who need not end up being Ph.D.s.